Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib

Background: Programmed death-ligand 1 (PD-L1) expression is associated with clinical outcomes of epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma (ADC) treated with tyrosine kinase inhibitors (TKIs). However, whether PD-L1 expression plays a role in anaplastic lymphoma kinase (ALK)-positive lung ADC is unknown. We aimed to evaluate the impact of PD-L1 in patients with ALK-positive lung ADC receiving crizotinib. Conclusion: Positive PD-L1 expression was associated with unfavorable clinical outcomes in patients with ALK-positive lung ADC receiving crizotinib. READ ARTICLE

The Oncologist DOI:10.1634/theoncologist.2020-0088

Authors: Yang CY, Liao WY, Ho CC, Chen KY, Tsai TH, Hsu CL, Liu YN, Su KY, Chang YL, Wu CT, Liao BC, Hsu CC, Hsu WH, Lee JH, Lin CC, Shih JY, Yang JC, Yu CJ.

Association of Programmed Death‐Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase‐Positive Lung Adenocarcinoma Receiving Crizotinib

Background. Programmed death-ligand 1 (PD-L1) expression is associated with clinical outcomes of epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma (ADC) treated with tyrosine kinase inhibitors (TKIs). However, whether PD-L1 expression plays a role in anaplastic lymphoma kinase (ALK)- positive lung ADC is unknown. We aimed to evaluate the impact of PD-L1 in patients with ALK-positive lung ADC receiv- ing crizotinib.
Materials and Methods. PD-L1 expression was identified by immunohistochemistry (IHC). Reverse transcriptase-polymerase chain reaction was used for ALK variant detection, and immunofluorescence-based multiplex staining was applied for exploring immune cells in tumor microenvironments.
Results. A total of 78 patients with ALK-positive advanced ADC were enrolled in our study, of whom 52 received crizotinib. Compared with EGFR/ALK wild-type tumors, PD-L1 expression was lower in ALK-positive ADC. ALK fusion variants
were identified in 32 patients, and those with ..... READ ARTICLE

The Oncologist DOI:10.1634/theoncologist.2020-0088

Authors: CHING-YAO YANG, WEI-YU LIAO, CHAO-CHI HO, KUAN-YU CHEN, TZU-HSIU TSAI, CHIA-LIN HSU, YI-NAN LIU, KANG-YI SU, YIH-LEONG CHANG, CHEN-TU WU, BIN-CHI LIAO, CHIA-CHI HSU, WEI-HSUN HSU, JIH-HSIANG LEE, CHIA-CHI LIN, JIN-YUAN SHIH, JAMES CHIH-HSIN YANG, CHONG-JEN YU

P114-26 ALK Fusion Variant Detection by Targeted RNA-Seq in TKIs Treated ALK-Positive Lung Adenocarcinoma

We retrospectively characterized fusion variant distribution in a cohort of ALK+ lung adenocarcinomas (ADC) with paired clinical data about treatments and outcomes.Diagnostic tumor tissue from advanced ALK+ (by FISH and/or IHC) ADC diagnosed from 2010 to 2018 and treated with single or multiple ALKis were collected (expanded cohort from Gobbini et al. Lung Cancer, 2017). The OncomineTM Solid Tumor Fusion Transcript Kit on an Ion PGM™ system and the Ion Reporter™ software were used to identify targeted ALK fusion gene products (ThermoFisher).Our analysis suggests that different ALK fusion variant might affect ALKi treatment duration in ALK+ lung ADC READ ARTICLE

Journal of Thoracic Oncology DOI:10.1016/j.jtho.2019.08.1177

Authors: F. Tabbò, E. Gobbini, L. Muscarella, A. Rigutto, D. Trombetta, A. Bonfitto, D. Galetta, E. Maiello, O. Martelli, M. Tiseo, P. Bordi, V. Scotti, L. Ghilardi, V. Gregorc, C. Sergi, S. Pilotto, A. Del, Conte, F. Cappuzzo, D. Cortinovis, G. Osman, C. Bareggi, M. Di Maio, A. Rossi, G. Rossi, E. Bria, M. Volante, G. Scagliotti, P. Graziano, S. Novello, L. Righi